In a recent study published in the journal Diabetes Care , a group of researchers evaluated the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). Study: Semaglutide and Cardiovascular Outcomes by Baseline HbA 1c and Change in HbA 1c in People With Overweight or Obesity but Without Diabetes in SELECT . Image Credit: Douglas Cliff / Shutterstock The prevalence of cardiovascular events increases from normoglycemia to diabetes, with elevated fasting glucose and dysglycemia as independent predictors of adverse outcomes.
High glucose levels contribute to coronary artery disease, peripheral artery disease, stroke, and heart failure. Lowering glucose within a target range is crucial for cardiovascular risk reduction. While lifestyle changes, metformin, and thiazolidinediones improve risk factors, they have not reduced cardiovascular events in prediabetes.
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have reduced cardiovascular events in type 2 diabetes patients with cardiovascular disease through mechanisms like reduced inflammation and improved risk factors. Further research is needed to understand the mechanisms and efficacy across different glycemic populations. The present SELECT trial was a multicenter, randomized, double-blind, placebo-controlled stu.
